Takeaways: The Canadian approval expands Epkinly into a second major lymphoma indication (after DLBCL), giving AbbVie a bispecific‑based triplet option in relapsed/refractory follicular ly...
Minjuvi Gains Accelerated Funding in Ontario for Relapsed/Refractory Follicular Lymphoma Incyte announced that Minjuvi (tafasitamab), in combination with R² (lenalidomide and rituximab), is now funded...
Takeaways: Roche’s dual-formulation (IV and SC) authorization for Lunsumio (mosunetuzumab) in Canada creates flexible, fixed-duration access for relapsed/refractory follicular lymphoma...
